Get the Stockscreener App
10.88
1.02%
0.11
Oric Pharmaceuticals Inc stock is traded at $10.88, with a volume of 1.05M.
It is up +1.02% in the last 24 hours and up +8.91% over the past month.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
See More
Previous Close:
$10.77
Open:
$10.91
24h Volume:
1.05M
Relative Volume:
1.03
Market Cap:
$1.06B
Revenue:
-
Net Income/Loss:
$-137.25M
P/E Ratio:
-5.7566
EPS:
-1.89
Net Cash Flow:
$-121.97M
1W Performance:
+6.35%
1M Performance:
+8.91%
6M Performance:
+36.86%
1Y Performance:
+14.77%
1-Day Range:
$10.78
$11.27
1-Week Range:
$10.06
$11.27
52-Week Range:
$3.8951
$14.67
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Name
Oric Pharmaceuticals Inc
Sector
Industry
Phone
(650) 388-5600
Address
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
10.88 | 1.05B | 0 | -137.25M | -121.97M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Oct-31-24 | Initiated | Wells Fargo | Overweight |
| Sep-06-24 | Initiated | Stifel | Buy |
| Feb-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-22-23 | Initiated | Wedbush | Outperform |
| Mar-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-21-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-16-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-18-22 | Resumed | Oppenheimer | Perform |
| Apr-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Mar-25-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-22-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-21 | Upgrade | Citigroup | Neutral → Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-13-20 | Initiated | Robert W. Baird | Outperform |
| Aug-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Citigroup | Neutral |
| May-19-20 | Initiated | Guggenheim | Buy |
| May-19-20 | Initiated | JP Morgan | Overweight |
| May-19-20 | Initiated | Jefferies | Buy |
View All
Oric Pharmaceuticals Inc Stock (ORIC) Latest News
167,502 Shares in Oric Pharmaceuticals, Inc. $ORIC Bought by Nuveen LLC - MarketBeat
Is ORIC Pharmaceuticals Inc. a cyclical or defensive stockJuly 2025 Fed Impact & Weekly High Conviction Trade Ideas - خودرو بانک
Oric Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | ORIC Stock News - GuruFocus
ORIC Pharmaceuticals’ Talent Retention Strategy and Stock Incentive Impact on Long-Term Value - AInvest
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biotech ORIC Pharmaceuticals Awards 371.5K Equity Incentives Package to Strategic New Hire - Stock Titan
Will earnings trigger a reversal in ORIC Pharmaceuticals Inc.Quarterly Market Review & Smart Allocation Stock Tips - Newser
Key metrics from ORIC Pharmaceuticals Inc.’s quarterly dataDip Buying & Free Fast Entry Momentum Trade Alerts - Newser
What’s the beta of ORIC Pharmaceuticals Inc. stockIndex Update & Precise Swing Trade Alerts - خودرو بانک
Is ORIC Pharmaceuticals Inc. meeting your algorithmic filter criteriaMarket Growth Report & Community Trade Idea Sharing - Newser
Oric Pharmaceuticals, Inc. $ORIC Shares Bought by Rafferty Asset Management LLC - MarketBeat
Layoff Tracker: AC Immune To Cut 30% of Workforce - biospace.com
Detecting price anomalies in ORIC Pharmaceuticals Inc. with AIWeekly Trade Analysis & Scalable Portfolio Growth Ideas - Newser
ORIC Pharmaceuticals Inc. recovery potential after sell offJuly 2025 Update & Short-Term High Return Ideas - Newser
Custom watchlist performance reports with ORIC Pharmaceuticals Inc.July 2025 Recap & Safe Capital Growth Stock Tips - Newser
ORIC Pharmaceuticals Inc. Attempts Reversal From Key SupportJuly 2025 Pullbacks & Fast Exit and Entry Trade Guides - beatles.ru
DAFNA Capital Management LLC Invests $1.35 Million in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Alkeon Capital Management LLC Increases Stake in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Guggenheim Assumes Coverage on ORIC Pharmaceuticals with Buy Rat - GuruFocus
Can ORIC Pharmaceuticals Inc. expand into new markets2025 Earnings Impact & Weekly Watchlist for Consistent Profits - خودرو بانک
MPM Bioimpact LLC Takes $7.81 Million Position in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Guggenheim initiates ORIC Pharmaceuticals stock with Buy rating on cancer drug potential - Investing.com Canada
Is ORIC Pharmaceuticals Inc. stock bottoming outTrade Volume Summary & AI Powered Buy and Sell Recommendations - Newser
Frazier Life Sciences Management L.P. Has $7.87 Million Stock Position in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Can trapped investors hope for a rebound in ORIC Pharmaceuticals Inc.Trade Entry Summary & Fast Gaining Stock Strategy Reports - Newser
Should value investors consider ORIC Pharmaceuticals Inc.July 2025 Macro Moves & Trade Opportunity Analysis - خودرو بانک
Combining machine learning predictions for ORIC Pharmaceuticals Inc.July 2025 Macro Moves & Community Verified Swing Trade Signals - Newser
What MACD signals say about ORIC Pharmaceuticals Inc.Trade Performance Summary & Verified Swing Trading Watchlists - Newser
ORIC Pharmaceuticals' Strategic Position in Overcoming Cancer Resistance - AInvest
Earnings Recap: Does ORIC Pharmaceuticals Inc. have pricing power2025 Macro Impact & Short-Term High Return Ideas - خودرو بانک
ORIC Pharmaceuticals Inc. stock prediction for this weekMarket Trend Review & Free Technical Confirmation Trade Alerts - Newser
What momentum shifts mean for ORIC Pharmaceuticals Inc.Weekly Stock Analysis & Capital Efficiency Focused Ideas - Newser
Real time pattern detection on ORIC Pharmaceuticals Inc. stock2025 Top Gainers & Verified Momentum Stock Alerts - Newser
Using fundamentals and technicals on ORIC Pharmaceuticals Inc.2025 Major Catalysts & Pattern Based Trade Signal System - Newser
How to interpret RSI for ORIC Pharmaceuticals Inc. stockTrade Entry Report & Reliable Price Breakout Signals - Newser
Is ORIC Pharmaceuticals Inc. still worth holding after the dipPortfolio Growth Summary & Weekly Top Gainers Trade List - Newser
Is ORIC Pharmaceuticals Inc. forming a breakout pattern2025 Retail Activity & Safe Swing Trade Setup Alerts - khodrobank.com
Real time breakdown of ORIC Pharmaceuticals Inc. stock performancePortfolio Return Summary & Detailed Earnings Play Alerts - Newser
Is ORIC Pharmaceuticals Inc. a candidate for recovery playQuarterly Trade Review & Free Accurate Trade Setup Notifications - Newser
Is ORIC Pharmaceuticals Inc. forming a bullish divergenceJuly 2025 Trade Ideas & High Accuracy Swing Entry Alerts - خودرو بانک
Does ORIC Pharmaceuticals Inc. have pricing powerPortfolio Update Summary & Growth Oriented Trading Recommendations - خودرو بانک
Oric Pharmaceuticals Inc Stock (ORIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Oric Pharmaceuticals Inc Stock (ORIC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Piscitelli Dominic | Chief Financial Officer |
Jun 24 '25 |
Sale |
10.50 |
32,466 |
341,039 |
68,317 |
| Piscitelli Dominic | Chief Financial Officer |
Jun 23 '25 |
Sale |
10.00 |
1,034 |
10,344 |
100,783 |
| You Angie | Director |
Jun 20 '25 |
Buy |
9.39 |
26,597 |
249,669 |
26,597 |
| You Angie | Director |
Jun 23 '25 |
Buy |
9.43 |
1,403 |
13,230 |
28,000 |
| Piscitelli Dominic | Chief Financial Officer |
Jun 12 '25 |
Sale |
10.00 |
300 |
3,000 |
101,817 |
| Piscitelli Dominic | Chief Financial Officer |
Jun 11 '25 |
Sale |
10.01 |
2,976 |
29,777 |
102,117 |
| Piscitelli Dominic | Chief Financial Officer |
Jun 10 '25 |
Sale |
10.00 |
324 |
3,240 |
105,093 |
| Piscitelli Dominic | Chief Financial Officer |
Jun 06 '25 |
Sale |
10.01 |
2,600 |
26,021 |
104,164 |
| Piscitelli Dominic | Chief Financial Officer |
Jun 09 '25 |
Sale |
10.00 |
300 |
3,000 |
103,864 |
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):